News Room provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
The Latest Media Conference
Conference on FY2025.12 Q1 Financial Results
Presentations:
FY2025 Q1 Overview
Dr. Osamu Okuda,
President & CEO
Overview of Development Pipeline
Tsukasa Kusano,
Executive Vice President, Head of Project & Lifecycle Management Unit
FY2025 Q1 Consolidated Financial Overview (Core)
Iwaaki Taniguchi,
Director, Executive Vice President & CFO
News
Topics about Advanced and sustainable patient-centric healthcare
We introduce Chugai's initiatives for "Patient-Centric," which we uphold as our highest priority "Core Value.
Features of the Strategic Alliance and Business Model “Alliance with Roche”
In 2002, Chugai started a strategic alliance with the Swiss company Roche, one of the world’s leading pharmaceutical companies. Under its unique business model, Chugai has realized its continuous growth.
While a member of the Roche Group, Chugai maintains its autonomous management and listing on the Tokyo Stock Exchange, enabling Chugai to focus on innovation with an emphasis on originality. This unprecedented business model contributes to enhancing Chugai’s corporate value and developing the Roche Group.
In this video, we will show the strategic alliance with Roche that forms the basis for this unique business model.
Features of the Strategic Alliance and Business Model “Transactions with Roche”
In 2002, Chugai started a strategic alliance with the Swiss
company Roche, one of the world’s leading pharmaceutical
companies.
Under its unique business model, Chugai has
realized its continuous growth.
In this video, we will present the financial impact that
transactions with Roche under the strategic alliance have on
Chugai.
The explanation will be divided into two parts:
“out-licensing of in-house products to Roche” and
“in-licensing of products from Roche.”